-transparent.png){kind=logo}
The ability of the anabolic steroid, stanozolol, to stimulate procollagenase production by human synovial and skin fibroblasts was examined in an in vitro assay system. Stanozolol is used therapeutically to treat a variety of connective tissue and vascular disorders and its clinical effects suggest that it can modulate connective tissue breakdown. The results showed that stanozolol was capable, in a dose dependent manner, of significantly stimulating procollagenase production by skin fibroblasts. However, in three synovial fibroblast lines no evidence was found of increased collagenase production following treatment with stanozolol; although the synovial fibroblasts secreted significantly increased amounts of procollagenase in response to IL-1. These results may shed some light on the mechanism of action in vivo of stanozolol in the treatment of connective tissue disorders.
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
March 1992,
Agents and actions,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
March 1994,
Agents and actions,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
December 1998,
The Journal of investigative dermatology,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
October 1988,
BMJ (Clinical research ed.),
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
May 1988,
Clinical science (London, England : 1979),
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
August 1983,
The Biochemical journal,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
November 1965,
Clinical pediatrics,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
September 1981,
British journal of clinical pharmacology,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
October 1985,
FEBS letters,
J K Wright, and
A J Smith, and
T E Cawston, and
B L Hazleman
September 1987,
The Journal of endocrinology,
